PharmiWeb.com - Global Pharma News & Resources
06-Feb-2024

INSERTING and REPLACING GE HealthCare Reports Fourth Quarter and Full Year 2023 Financial Results

Delivers Strong Financial and Operating Performance in First Year as Public Company

Fourth Quarter 2023

  • Revenue growth was 5% year-over-year; Organic revenue growth* of 5%
  • Net income margin was 7.7% versus 11.2% for the prior year; Adjusted Earnings Before Interest and Taxes (EBIT) margin* was 16.1% versus the fourth quarter of 2022 Standalone Adjusted EBIT margin* of 16.1%
  • Cash flow from operating activities was $1.1 billion versus $1.1 billion for the prior year; Free cash flow* was $956 million versus $987 million; repaid $850 million of debt in the fourth quarter of 2023 and an additional $150 million of debt in January 2024

Full Year 2023

  • Revenue growth was 7% year-over-year; Organic revenue growth* of 8%
  • Net income margin was 8% versus 10.4% for the prior year; Adjusted EBIT margin* was 15.1% versus 2022 Standalone Adjusted EBIT margin* of 14.5%
  • Cash flow from operating activities was $2.1 billion versus $2.1 billion for the prior year, and Free cash flow* was $1.7 billion versus $1.8 billion last year, due to standalone interest and postretirement benefit payments
  • Company provides 2024 financial guidance, demonstrating progress toward medium-term financial targets

 

CHICAGO--(BUSINESS WIRE)--Insertion of Fourth Quarter 2023 P&L labeled "Consolidated and Combined Statements of Income" following the 2024 Guidance information.

The updated release reads:

GE HEALTHCARE REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS

Delivers Strong Financial and Operating Performance in First Year as Public Company

Fourth Quarter 2023

  • Revenue growth was 5% year-over-year; Organic revenue growth* of 5%
  • Net income margin was 7.7% versus 11.2% for the prior year; Adjusted Earnings Before Interest and Taxes (EBIT) margin* was 16.1% versus the fourth quarter of 2022 Standalone Adjusted EBIT margin* of 16.1%
  • Cash flow from operating activities was $1.1 billion versus $1.1 billion for the prior year; Free cash flow* was $956 million versus $987 million; repaid $850 million of debt in the fourth quarter of 2023 and an additional $150 million of debt in January 2024

Full Year 2023

  • Revenue growth was 7% year-over-year; Organic revenue growth* of 8%
  • Net income margin was 8% versus 10.4% for the prior year; Adjusted EBIT margin* was 15.1% versus 2022 Standalone Adjusted EBIT margin* of 14.5%
  • Cash flow from operating activities was $2.1 billion versus $2.1 billion for the prior year, and Free cash flow* was $1.7 billion versus $1.8 billion last year, due to standalone interest and postretirement benefit payments
  • Company provides 2024 financial guidance, demonstrating progress toward medium-term financial targets

GE HealthCare (Nasdaq: GEHC), a leading global precision care innovator, today reported financial results for the fourth quarter ended December 31, 2023.

GE HealthCare President and CEO Peter Arduini said, “After our first year as a publicly traded company, I’m pleased to announce robust fourth quarter and full year results. This strong financial performance is a testament to our dedicated team and successful execution of our precision care strategy. We’ve made significant strides, including investing over $1 billion in R&D for future growth, helping drive more than 40 innovations in 2023. We bolstered our market position with strategic acquisitions, while at the same time paying down $1 billion in debt, setting a solid foundation for continued growth. We’re confident heading into 2024 amid the backdrop of an improved capital equipment landscape.”

Fourth Quarter 2023 Total Company Financial Performance

  • Revenues of $5.2 billion increased 5% on both a reported and Organic* basis year-over-year, driven by price and volume.
  • Total company book-to-bill was strong at 1.05 times, defined as Total orders divided by Total revenues, as the Company continues to build a robust backlog. Total company orders increased 3% organically year-over-year.
  • Net income attributable to GE HealthCare was $403 million versus $554 million for the prior year, and Adjusted EBIT* was $837 million versus $844 million.
  • Net income margin was 7.7% versus 11.2% for the prior year, down 350 basis points (bps) primarily impacted by standalone interest expense. Adjusted EBIT margin* was 16.1% versus 17.1%, down 100 bps. Adjusted EBIT margin* for the fourth quarter of 2023 was flat versus the Company’s estimated fourth quarter 2022 Standalone Adjusted EBIT margin* of 16.1% as benefits from productivity and price were offset primarily by investments.
  • Earnings per share (EPS) from continuing operations were $0.88 versus $1.21, down $0.33 from the prior year. Adjusted EPS* was $1.18 versus $1.31, down $0.13 from the prior year. Both comparisons were impacted by standalone interest expense. Adjusted EPS* for the fourth quarter of 2023 grew $0.12 versus the Company’s estimated fourth quarter 2022 Standalone Adjusted EPS* of $1.06.
  • Cash flow from operating activities was $1.1 billion, down $13 million year-over-year. Free cash flow* was $956 million, down $31 million year-over-year. Both metrics were primarily impacted by standalone interest and postretirement benefit payments. The Company repaid $850 million of debt in the fourth quarter of 2023 and an additional $150 million of debt in January 2024.

Fourth Quarter 2023 Segment Financial Performance

Imaging

  • Revenues of $2.8 billion increased 4% on both a reported and Organic* basis year-over-year.
  • Segment EBIT was $337 million versus $321 million for the prior year.
  • Segment EBIT margin was 11.9% versus 11.8% for the prior year.

Ultrasound

  • Revenues of $944 million declined 1% reported and 2% on an Organic* basis year-over-year.
  • Segment EBIT was $244 million versus $285 million for the prior year.
  • Segment EBIT margin was 25.8% versus 29.8% for prior year.

Patient Care Solutions

  • Revenues of $827 million increased 5% reported and 4% on an Organic* basis year-over-year.
  • Segment EBIT was $110 million versus $130 million for the prior year.
  • Segment EBIT margin was 13.3% versus 16.5% for the prior year.

Pharmaceutical Diagnostics

  • Revenues of $591 million increased 25% reported and 23% on an Organic* basis year-over-year.
  • Segment EBIT was $144 million versus $109 million for the prior year.
  • Segment EBIT margin was 24.4% versus 23.0% for the prior year.

Full Year 2023 Total Company Financial Performance

  • Revenues of $19.6 billion increased 7% year-over-year and 8% on an Organic* basis with growth across all segments and regions.
  • Total company book-to-bill was 1.03 times, as orders dollars outpaced revenues. Total company orders increased 3% organically year-over-year.
  • Net income attributable to GE HealthCare was $1.6 billion versus $1.9 billion for the prior year, and Adjusted EBIT* was $3.0 billion versus $2.9 billion in the same period last year.
  • Net income margin was 8% versus 10.4% for the prior year, down 240 bps, primarily impacted by standalone interest expense. Adjusted EBIT margin* was 15.1% versus 15.6% last year, down 50 bps. Adjusted EBIT margin* for the full year 2023 was up 60 bps versus the Company’s estimated full year 2022 Standalone Adjusted EBIT margin* of 14.5% last year. Margin benefited from productivity, price, and volume, and was partially offset by inflation.
  • EPS from continuing operations was $3.04 compared to $4.18 for full year 2022, down $1.14 from the prior year. Adjusted EPS* was $3.93, versus $4.63 in prior year. Both comparisons were impacted by standalone interest expense. Adjusted EPS* for the full year 2023 grew $0.55 versus the Company’s estimated full year 2022 Standalone Adjusted EPS* of $3.38.
  • Cash flow from operating activities was $2.1 billion, down $33 million year-over-year, and Free cash flow* was $1.7 billion, down $113 million year-over-year, due to standalone interest and postretirement benefit payments.
  • Cash flow conversion, defined as cash from operating activities divided by net income attributable to GE HealthCare, was 134% while Free cash flow conversion* was 95% for 2023.

Growth and Innovation

2024 Guidance

Full year 2024 guidance is as follows:

  • Organic revenue growth* of approximately 4% year-over-year.
  • Adjusted EBIT margin* in the range of 15.6% to 15.9%, reflecting an expansion of 50 to 80 basis points versus 2023 Adjusted EBIT margin* of 15.1%.
  • Adjusted effective tax rate (ETR)* in the range of 23% to 25%.
  • Adjusted EPS* in the range of $4.20 to $4.35, representing 7% to 11% growth versus Adjusted EPS* of $3.93 for 2023.
  • Free cash flow* of approximately $1.8 billion.

The Company provides its outlook on a non-GAAP basis. Refer to the Non-GAAP Financial Measures in Outlook section below for more details.

 

Consolidated and Combined Statements of Income

 

 

 

 

 

Unaudited

For the three months ended December 31

 

For the years ended December 31

(In millions, except per share amounts)

 

2023

 

 

2022

 

 

 

2023

 

 

2022

 

Sales of products

$

3,597

 

$

3,342

 

 

$

13,127

 

$

12,044

 

Sales of services

 

1,609

 

 

1,596

 

 

 

6,425

 

 

6,297

 

Total revenues

 

5,206

 

 

4,938

 

 

 

19,552

 

 

18,341

 

Cost of products

 

2,268

 

 

2,150

 

 

 

8,465

 

 

7,975

 

Cost of services

 

782

 

 

856

 

 

 

3,165

 

 

3,187

 

Gross profit

 

2,156

 

 

1,932

 

 

 

7,922

 

 

7,179

 

Selling, general, and administrative

 

1,152

 

 

884

 

 

 

4,282

 

 

3,631

 

Research and development

 

315

 

 

271

 

 

 

1,205

 

 

1,026

 

Total operating expenses

 

1,467

 

 

1,155

 

 

 

5,487

 

 

4,657

 

Operating income

 

689

 

 

777

 

 

 

2,435

 

 

2,522

 

Interest and other financial charges – net

 

131

 

 

59

 

 

 

542

 

 

77

 

Non-operating benefit (income) costs

 

(50

)

 

(1

)

 

 

(382

)

 

(5

)

Other (income) expense – net

 

(1

)

 

1

 

 

 

(86

)

 

(62

)

Income from continuing operations before income taxes

 

609

 

 

718

 

 

 

2,361

 

 

2,512

 

Benefit (provision) for income taxes

 

(193

)

 

(151

)

 

 

(743

)

 

(563

)

Net income from continuing operations

 

416

 

 

567

 

 

 

1,618

 

 

1,949

 

Income (loss) from discontinued operations, net of taxes

 

 

 

6

 

 

 

(4

)

 

18

 

Net income

 

416

 

 

573

 

 

 

1,614

 

 

1,967

 

Net (income) loss attributable to noncontrolling interests

 

(13

)

 

(19

)

 

 

(46

)

 

(51

)

Net income attributable to GE HealthCare

 

403

 

 

554

 

 

 

1,568

 

 

1,916

 

Deemed preferred stock dividend of redeemable noncontrolling interest

 

 

 

 

 

 

(183

)

 

 

Net income attributable to GE HealthCare common stockholders

$

403

 

$

554

 

 

$

1,385

 

$

1,916

 

 

 

 

 

 

 

Earnings per share from continuing operations attributable to GE HealthCare common stockholders:

 

 

 

 

 

Basic

$

0.89

 

$

1.21

 

 

$

3.06

 

$

4.18

 

Diluted

 

0.88

 

 

1.21

 

 

 

3.04

 

 

4.18

 

Earnings per share attributable to GE HealthCare common stockholders:

 

 

 

 

 

Basic

$

0.89

 

$

1.22

 

 

$

3.05

 

$

4.22

 

Diluted

 

0.88

 

 

1.22

 

 

 

3.03

 

 

4.22

 

Weighted-average number of shares outstanding:

 

 

 

 

 

Basic

 

455

 

 

454

 

 

 

455

 

 

454

 

Diluted

 

458

 

 

454

 

 

 

458

 

 

454

 

Consolidated and Combined Statements of Income

 

 

 

For the years ended December 31

(In millions, except per share amounts)

 

2023

 

 

2022

 

 

2021

 

Sales of products

$

13,127

 

$

12,044

 

$

11,165

 

Sales of services

 

6,425

 

 

6,297

 

 

6,420

 

Total revenues

 

19,552

 

 

18,341

 

 

17,585

 

Cost of products

 

8,465

 

 

7,975

 

 

7,196

 

Cost of services

 

3,165

 

 

3,187

 

 

3,215

 

Gross profit

 

7,922

 

 

7,179

 

 

7,174

 

Selling, general, and administrative

 

4,282

 

 

3,631

 

 

3,563

 

Research and development

 

1,205

 

 

1,026

 

 

816

 

Total operating expenses

 

5,487

 

 

4,657

 

 

4,379

 

Operating income

 

2,435

 

 

2,522

 

 

2,795

 

Interest and other financial charges – net

 

542

 

 

77

 

 

40

 

Non-operating benefit (income) costs

 

(382

)

 

(5

)

 

3

 

Other (income) expense – net

 

(86

)

 

(62

)

 

(123

)

Income from continuing operations before income taxes

 

2,361

 

 

2,512

 

 

2,875

 

Benefit (provision) for income taxes

 

(743

)

 

(563

)

 

(600

)

Net income from continuing operations

 

1,618

 

 

1,949

 

 

2,275

 

Income (loss) from discontinued operations, net of taxes

 

(4

)

 

18

 

 

18

 

Net income

 

1,614

 

 

1,967

 

 

2,293

 

Net (income) loss attributable to noncontrolling interests

 

(46

)

 

(51

)

 

(46

)

Net income attributable to GE HealthCare

 

1,568

 

 

1,916

 

 

2,247

 

Deemed preferred stock dividend of redeemable noncontrolling interest

 

(183

)

 

 

 

 

Net income attributable to GE HealthCare common stockholders

$

1,385

 

$

1,916

 

$

2,247

 

 

 

 

 

Earnings per share from continuing operations attributable to GE HealthCare common stockholders:

 

 

 

Basic

$

3.06

 

$

4.18

 

$

4.91

 

Diluted

 

3.04

 

 

4.18

 

 

4.91

 

Earnings per share attributable to GE HealthCare common stockholders:

 

 

 

Basic

$

3.05

 

$

4.22

 

$

4.95

 

Diluted

 

3.03

 

 

4.22

 

 

4.95

 

Weighted-average number of shares outstanding:

 

 

 

Basic

 

455

 

 

454

 

 

454

 

Diluted

 

458

 

 

454

 

 

454

 

Consolidated and Combined Statements of Financial Position

 

 

As of

(In millions, except share and per share amounts)

December 31, 2023

December 31, 2022

Cash, cash equivalents, and restricted cash

$

2,504

 

$

1,445

 

Receivables – net of allowances of $98 and $91

 

3,525

 

 

3,295

 

Due from related parties

 

32

 

 

17

 

Inventories

 

1,960

 

 

2,155

 

Contract and other deferred assets

 

1,000

 

 

989

 

All other current assets

 

389

 

 

417

 

Current assets

 

9,410

 

 

8,318

 

Property, plant, and equipment – net

 

2,500

 

 

2,314

 

Goodwill

 

12,936

 

 

12,813

 

Other intangible assets – net

 

1,253

 

 

1,520

 

Deferred income taxes

 

4,474

 

 

1,550

 

All other assets

 

1,881

 

 

1,024

 

Total assets

$

32,454

 

$

27,539

 

Short-term borrowings

$

1,006

 

$

15

 

Accounts payable

 

2,947

 

 

2,944

 

Due to related parties

 

99

 

 

146

 

Contract liabilities

 

1,918

 

 

1,896

 

All other current liabilities

 

3,011

 

 

2,190

 

Current liabilities

 

8,981

 

 

7,191

 

Long-term borrowings

 

8,436

 

 

8,234

 

Compensation and benefits

 

5,782

 

 

549

 

Deferred income taxes

 

68

 

 

370

 

All other liabilities

 

1,877

 

 

1,603

 

Total liabilities

 

25,144

 

 

17,947

 

Commitments and contingencies

 

 

Redeemable noncontrolling interests

 

165

 

 

230

 

Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 455,342,290 shares issued and outstanding as of December 31, 2023; 100 shares issued and outstanding as of December 31, 2022

 

5

 

 

 

Additional paid-in capital

 

6,493

 

 

 

Retained earnings

 

1,326

 

 

 

Net parent investment

 

 

 

11,235

 

Accumulated other comprehensive income (loss) – net

 

(691

)

 

(1,878

)

Total equity attributable to GE HealthCare

 

7,133

 

 

9,357

 

Noncontrolling interests

 

12

 

 

5

 

Total equity

 

7,145

 

 

9,362

 

Total liabilities, redeemable noncontrolling interests, and equity

$

32,454

 

$

27,539

 

 
 

Consolidated and Combined Statements of Cash Flows

 

 

 

 

For the years ended December 31

(In millions)

 

2023

 

 

2022

 

 

2021

 

Net income

$

1,614

 

$

1,967

 

$

2,293

 

Less: Income (loss) from discontinued operations, net of taxes

 

(4

)

 

18

 

 

18

 

Net income from continuing operations

$

1,618

 

$

1,949

 

$

2,275

 

Adjustments to reconcile Net income from continuing operations to Cash from (used for) operating activities

 

 

 

Depreciation of property, plant, and equipment

 

248

 

 

228

 

 

225

 

Amortization of intangible assets

 

362

 

 

405

 

 

400

 

Gain on fair value remeasurement of contingent consideration

 

(17

)

 

(65

)

 

 

Net periodic postretirement benefit plan (income) expense

 

(332

)

 

9

 

 

25

 

Postretirement plan contributions

 

(357

)

 

(18

)

 

(20

)

Share-based compensation

 

114

 

 

67

 

 

76

 

Provision for income taxes

 

743

 

 

563

 

 

600

 

Cash paid during the year for income taxes

 

(474

)

 

(851

)

 

(615

)

Changes in operating assets and liabilities, excluding the effects of acquisitions and dispositions:

 

 

 

Receivables

 

(185

)

 

(231

)

 

(1,336

)

Due from related parties

 

4

 

 

13

 

 

157

 

Inventories

 

111

 

 

(402

)

 

(435

)

Contract and other deferred assets

 

10

 

 

(222

)

 

23

 

Accounts payable

 

(13

)

 

481

 

 

263

 

Due to related parties

 

(84

)

 

(33

)

 

(21

)

Contract liabilities

 

26

 

 

138

 

 

(21

)

All other operating activities

 

327

 

 

103

 

 

11

 

Cash from (used for) operating activities – continuing operations

 

2,101

 

 

2,134

 

 

1,607

 

Cash flows – investing activities

 

 

 

Additions to property, plant and equipment and internal-use software

 

(387

)

 

(310

)

 

(248

)

Dispositions of property, plant, and equipment

 

1

 

 

4

 

 

15

 

Purchases of businesses, net of cash acquired

 

(147

)

 

 

 

(1,481

)

All other investing activities

 

(25

)

 

(92

)

 

(47

)

Cash from (used for) investing activities – continuing operations

 

(558

)

 

(398

)

 

(1,761

)

Cash flows – financing activities

 

 

 

Net increase (decrease) in borrowings (maturities of 90 days or less)

 

(12

)

 

9

 

 

(7

)

Newly issued debt, net of debt issuance costs (maturities longer than 90 days)

 

2,006

 

 

8,198

 

 

5

 

Repayments and other reductions (maturities longer than 90 days)

 

(855

)

 

(3

)

 

(10

)

Dividends paid to stockholders

 

(41

)

 

 

 

 

Redemption of noncontrolling interests

 

(211

)

 

 

 

 

Net transfers (to) from GE

 

(1,317

)

 

(8,934

)

 

(238

)

All other financing activities

 

(48

)

 

(92

)

 

(13

)

Cash from (used for) financing activities – continuing operations

 

(478

)

 

(822

)

 

(263

)

Cash from (used for) operating activities – discontinued operations

 

 

 

(21

)

 

 

Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash

 

(10

)

 

(3

)

 

(34

)

Increase (decrease) in cash, cash equivalents, and restricted cash

 

1,055

 

 

890

 

 

(451

)

Cash, cash equivalents, and restricted cash at beginning of year

 

1,451

 

 

561

 

 

1,012

 

Cash, cash equivalents, and restricted cash as of December 31

$

2,506

 

$

1,451

 

$

561

 

 

 

 

 

Supplemental disclosure of cash flows information

 

 

 

Cash paid during the year for interest

$

(570

)

$

 

$

(21

)

Non-cash investing activities

 

 

 

Acquired but unpaid property, plant, and equipment

$

140

 

$

136

 

$

93

 

 
 
 

Non-GAAP Financial Measures

The non-GAAP financial measures presented in this press release are supplemental measures of GE HealthCare’s performance and its liquidity that the Company believes will help investors understand its financial condition, cash flows, and operating results and assess its future prospects. The Company believes that presenting these non-GAAP financial measures, in addition to the corresponding U.S. GAAP financial measures, are important supplemental measures that exclude non-cash or other items that may not be indicative of or related to its core operating results and the overall health of the Company. The Company believes these non-GAAP financial measures provide investors greater transparency to the information used by management for its operational decision-making and allow investors to see results “through the eyes of management.” The Company believes that providing this information assists investors in understanding its operating performance and the methodology used by management to evaluate and measure such performance. When read in conjunction with the Company’s U.S. GAAP results, these non-GAAP financial measures provide a baseline for analyzing trends in the Company’s underlying businesses and can be used by management as one basis for making financial, operational, and planning decisions. Finally, these measures are often used by analysts and other interested parties to evaluate companies in the Company’s industry.

Management recognizes that these non-GAAP financial measures have limitations, including that they may be calculated differently by other companies or may be used under different circumstances or for different purposes, thereby affecting their comparability from company to company. In order to compensate for these and the other limitations, management does not consider these measures in isolation from or as alternatives to the comparable financial measures determined in accordance with U.S. GAAP. Readers should review the reconciliations and should not rely on any single financial measure to evaluate the Company’s business.

The Company defines these non-GAAP financial measures as:

  • Organic revenue: Total revenues excluding the effects of: (1) net sales from recent acquisitions and dispositions with less than a full year of comparable net sales; and (2) foreign currency exchange rate fluctuations in order to present revenue on a constant currency basis.
  • Organic revenue growth rate: Rate of change when comparing Organic revenue, period over period.
  • Adjusted EBIT: Net income attributable to GE HealthCare excluding the effects of: (1) Interest and other financial charges – net; (2) Non-operating benefit (income) costs; (3) Provision (benefit) for income taxes; (4) Income (loss) from discontinued operations, net of taxes; (5) Net (income) loss attributable to noncontrolling interests; (6) restructuring costs; (7) acquisition and disposition-related charges (benefits); (8) Spin-Off and separation costs; (9) (gain) loss on business and asset dispositions; (10) amortization of acquisition-related intangible assets; and (11) investment revaluation (gain) loss. In addition, the Company may from time to time consider excluding other nonrecurring items to enhance comparability between periods.
  • Adjusted EBIT margin: Adjusted EBIT divided by Total revenues for the same period.
  • Standalone Adjusted EBIT: Adjusted EBIT including the effects of recurring and on-going costs to operate new functions required for a standalone company that management believes provide a better depiction of the operations of GE HealthCare as a standalone company.
  • Standalone Adjusted EBIT margin: Standalone Adjusted EBIT divided by Total revenues for the same period.

The Company believes that Organic revenue and Organic revenue growth rate, by excluding the effect of acquisitions, dispositions, and foreign currency rate fluctuations, provide management and investors with additional understanding of the Company’s core, top-line operating results and greater visibility into underlying revenue trends of its established, ongoing operations. Organic revenue and Organic revenue growth rate also provide greater insight regarding the overall demand for its products and services.

The Company believes Adjusted EBIT, Adjusted EBIT margin, Standalone Adjusted EBIT, and Standalone Adjusted EBIT margin provide management and investors with additional understanding of its business by highlighting the results from ongoing operations and the underlying profitability factors. These metrics exclude interest expense, interest income, non-operating benefit (income) costs, and tax expense, as well as non-recurring and/or non-cash items, which may have a material impact on the Company’s results. The Company believes this provides additional insight into how its businesses are performing, on a normalized basis. However, these non-GAAP financial measures should not be construed as inferring that the Company’s future results will be unaffected by the items for which the measure adjusts.​

  • Adjusted net income: Net income attributable to GE HealthCare excluding (1) Non-operating benefit (income) costs; (2) restructuring costs; (3) acquisition and disposition-related charges (benefits); (4) Spin-Off and separation costs; (5) (gain) loss on business and asset dispositions; (6) amortization of acquisition-related intangible assets; (7) investment revaluation (gain) loss; (8) tax effect of reconciling items (items 1-7); (9) certain tax adjustments as described in Adjusted tax expense definition below and (10) Income (loss) from discontinued operations, net of taxes.

Contacts

Investor Relations Contact:
Carolynne Borders
+1-631-662-4317
carolynne.borders@gehealthcare.com

Media Contact:
Tor Constantino
+1-585-441-1658
tor.constantino@gehealthcare.com


Read full story here

Editor Details

  • Company:
    • Businesswire
Last Updated: 06-Feb-2024